The AstraZeneca cancer drug spinoff floated above its range in an upsized initial public offering and now has a market cap topping $2bn.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Genscript Biotech’s subsidiary Legend Biotech, which agreed to an investment worth nearly $151m from Eli Lilly and Johnson & Johnson last month, has filed to go public.

GV and Tyson Ventures invested in an $18m funding round for Clear Labs that has now raised $62m altogether from backers also including Dentsu and Tencent.

Continental Grain-backed RNA material producer GreenLight Biosciences is hoping to supply ingredients for RNA-based coronavirus vaccines after securing $17m in funding.

Immune cell mapping technology developer Immunai has emerged from stealth to commercialise inventions from Stanford and PICI labs.

Intel Capital has invested at least $132m in 12 companies so far this year and is on its way to putting between $300m and $500m into startups by the end of 2020.

The Harvard motor neurone disease drug developer secured Mitsui, Sanford Biosciences and existing backer Amgen Ventures for its series A round.

Dai-ichi Life Insurance, Essential Pharma and Medi-Future were among the investors in a round that brought the pre-clinical drug developer's funding haul to $33.1m.